Angiotensin receptor blockers and COVID-19

Pharmacol Res. 2020 Jun;156:104832. doi: 10.1016/j.phrs.2020.104832. Epub 2020 Apr 15.

Abstract

Angiotensin Receptor Blockers (ARBs) exhibit major pleiotropic protecting effects beyond their antihypertensive properties, including reduction of inflammation. ARBs directly protect the lung from the severe acute respiratory syndrome as a result of viral infections, including those from coronavirus. The protective effect of ACE2 is enhanced by ARB administration. For these reasons ARB therapy must be continued for patients affected by hypertension, diabetes and renal disease, comorbidities of the current COVID-19 pandemic. Controlled clinical studies should be conducted to determine whether ARBs may be included as additional therapy for COVID-19 patients.

Keywords: ACE2; Angiotensin receptor blockers; COVID-19; Coronavirus; SARS-CoV-2.

Publication types

  • Letter
  • Comment

MeSH terms

  • Angiotensin Receptor Antagonists
  • Betacoronavirus
  • COVID-19
  • Coronavirus Infections
  • Diabetes Mellitus*
  • Humans
  • Hypertension*
  • Pandemics
  • Peptidyl-Dipeptidase A
  • Pneumonia, Viral
  • SARS-CoV-2

Substances

  • Angiotensin Receptor Antagonists
  • Peptidyl-Dipeptidase A